Active	Status	Sponsor type	Region	Phase	Filter
11 Active 4 Inactive 15 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Fenske, Timothy
NCT04212013: A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma	Active, not recruiting	3	23	US	Ibrutinib, Rituximab, Placebo	Memorial Sloan Kettering Cancer Center, Pharmacyclics LLC.	Marginal Zone Lymphoma	06/24	03/27
Chhabra, Saurabh
NCT04776018: A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)	Terminated	1/2	27	Canada, US	TAK-981, Mezagitamab, Daratumumab and Hyaluronidase-fihj	Takeda	Relapsed and/or Refractory Multiple Myeloma (RRMM)	08/23	11/23
NCT04756726: Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma	Recruiting	1/2	158	US	CFT7455, Dexamethasone Oral	C4 Therapeutics, Inc.	Multiple Myeloma, Lymphoma, Non-Hodgkin's	09/25	12/25
NCT04318327: BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma	Active, not recruiting	1	96	US, RoW	PHE885	Novartis Pharmaceuticals	Multiple Myeloma	02/26	02/26
UNIVERSAL, NCT04093596: Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma Data from UNIVERSAL trial for r/r multiple myeloma Jan 2023 - Jan 2023: Data from UNIVERSAL trial for r/r multiple myeloma Dose escalation data from UNIVERSAL trial in heavily pretreated r/r multiple myeloma Nov 2022 - Nov 2022: Dose escalation data from UNIVERSAL trial in heavily pretreated r/r multiple myeloma Safety and tolerability data from UNIVERSAL trial for multiple myeloma Nov 2022 - Nov 2022: Safety and tolerability data from UNIVERSAL trial for multiple myeloma Data from UNIVERSAL trial in combination with nirogacestat for r/r multiple myeloma at ASH 2021 Dec 2021 - Dec 2021: Data from UNIVERSAL trial in combination with nirogacestat for r/r multiple myeloma at ASH 2021 Initial data from UNIVERSAL trial in combination with nirogacestat for r/r multiple myeloma at ASCO 2021 Apr 2021 - Apr 2021: Initial data from UNIVERSAL trial in combination with nirogacestat for r/r multiple myeloma at ASCO 2021 Initiated dosing for UNIVERSAL study in combination with nirogacestat for r/r multiple myeloma Apr 2021 - Apr 2021: Initiated dosing for UNIVERSAL study in combination with nirogacestat for r/r multiple myeloma Data from UNIVERSAL trial for r/r multiple myeloma at ASH 2020 Dec 2020 - Dec 2020: Data from UNIVERSAL trial for r/r multiple myeloma at ASH 2020 More	Active, not recruiting	1	132	US	ALLO-715, ALLO-647, Fludarabine, Cyclophosphamide, Nirogacestat	Allogene Therapeutics	Relapsed/Refractory Multiple Myeloma	09/27	09/27
Pasquini, Marcelo
No trials found